<DOC>
	<DOCNO>NCT00005860</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness oxaliplatin without floxuridine leucovorin treat patient metastatic cancer peritoneum .</brief_summary>
	<brief_title>Oxaliplatin With Or Without Floxuridine Leucovorin Treating Patients With Metastatic Cancer Peritoneum</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose intraperitoneal oxaliplatin without intraperitoneal floxuridine leucovorin calcium patient metastatic cancer confine peritoneal cavity . - Determine dose limit nondose limit toxicity pharmacokinetics treatment regimens patient population . OUTLINE : This dose escalation study oxaliplatin . Patients receive intraperitoneal ( IP ) oxaliplatin 1 hour day 1 every 2 week 2 course . Beginning course 3 , patient receive oxaliplatin floxuridine leucovorin calcium IP day 1 floxuridine leucovorin calcium IP alone day 2 3 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Patients complete surgical resection disease receive total 6 course combination chemotherapy . Cohorts 3-6 patient receive escalate dos oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 3-40 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic unresectable cancer largely confine peritoneal cavity Fully resect and/or electrocauterized metastatic disease involve peritoneum ( stage IV , residual disease ) allow No know brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal SGOT/SGPT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No history allergy platinum compound antiemetic would preclude study No uncontrolled illness ( e.g. , active infection ) No evidence neuropathy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior cytotoxic chemotherapy ( 6 week mitomycin nitrosoureas ) recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Other : No concurrent investigational agent No concurrent antiretroviral therapy ( HAART )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>insulinoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>regional pheochromocytoma</keyword>
	<keyword>metastatic pheochromocytoma</keyword>
	<keyword>recurrent pheochromocytoma</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>malignant ascites</keyword>
	<keyword>newly diagnose carcinoma unknown primary</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>pseudomyxoma peritonei</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>recurrent carcinoma unknown primary</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>